COVID-19 and Endocrine and Metabolic Diseases: An Updated Statement from the European Society of Endocrinology

May 2021 in “ Endocrine ”

Manel Puig-Domingo, Mónica Marazuela, Bülent O. Yildiz, Andrea Giustina

diabetes obesity glycemic control metformin statins hypocalcemia vitamin D deficiency blood sugar control glucophage lipitor low calcium vitamin D

TLDR People with diabetes or obesity should manage their conditions carefully as they have a higher risk of severe COVID-19.

The European Society of Endocrinology's updated statement from May 2021 addresses the interplay between COVID-19 and endocrine and metabolic diseases, particularly emphasizing the importance of managing diabetes and obesity in the context of the pandemic. Diabetes is associated with increased severity and mortality in COVID-19 patients, and the statement advises that careful diabetes management is essential. Obesity is highlighted as a risk factor for worse COVID-19 outcomes, with a study of over 100,000 individuals showing a hazard ratio of 1.23 for obesity, indicating a higher risk of infection. The document also notes that obesity was the top risk factor for COVID-19 hospitalizations in the US, accounting for 30.2% of cases. It recommends considering patients with obesity as a higher risk group and suggests earlier intensive treatment. The statement also discusses the potential diabetogenic effect of the virus, the importance of glycemic control, and the continuation of certain medications like metformin and statins during hospitalization. Additionally, it touches on the nutritional consequences of COVID-19, the commonality of hypocalcemia, and the exacerbation of negative outcomes due to vitamin D deficiency. The document concludes with a "decalog" for managing endocrine aspects of COVID-19, advocating for vaccination, careful monitoring, and the use of telemedicine.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

41 citations, February 2021 in “Cureus”

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

41 citations, February 2021 in “Cureus”

Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.

research Male Balding Is a Major Risk Factor for Severe COVID-19

29 citations, July 2020 in “Journal of The American Academy of Dermatology”

Men with severe balding have a higher risk of getting very sick from COVID-19.

research Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign'

119 citations, May 2020 in “Journal of The American Academy of Dermatology”

Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.

Related Community Posts Join

6 / 133 results

community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

in Research 830 upvotes 6 months ago

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

community Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

in Research 864 upvotes 4 months ago

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

community Connection between finasteride and nafld?

in Research/Science 4 upvotes 6 months ago

Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.

community Wouldn’t it be funny if there already was a drug that existed which reactivated sleeping follicles? It would be our own version of Ozempic

in Research/Science 204 upvotes 2 months ago

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

community Physio-metabolic method of treating androgenic alopecia. Cold receptors. The relationship between DHT, cold receptors, minoxidil and antiandrogens.

in Research/Science 2 upvotes 2 months ago

A method for treating androgenic alopecia using minoxidil, antiandrogens, exercise, and cold exposure to promote hair growth. Environmental factors and lifestyle changes, like diet and exercise, can improve treatment effectiveness.

community What treatment should I take? and is it really bad?

in Treatment 4 upvotes 5 months ago

OP is experiencing significant hair loss despite GFC and PRP treatments and has abnormal lab results. They are advised to consult a hair-focused dermatologist for further evaluation.

Similar Research

5 / 1000+ results

research Polycystic Ovary Syndrome and Cardiovascular Disease

February 2012 in “InTech eBooks”

PCOS increases the risk of heart disease and type 2 diabetes in women.

research Type 2 Diabetes, Metabolic Syndrome, and Lipid Metabolism

January 2014 in “S. Karger AG eBooks”

Type 2 diabetes in youth is increasing, with high treatment failure rates and more severe than Type 1; certain drugs can lower lipid levels effectively with varying side effects, and apples may benefit heart health like statins but with fewer side effects.

research Polycystic Ovary Syndrome: Etiology, Pathogenesis, and Diagnosis

991 citations, January 2011 in “Nature Reviews Endocrinology”

The document concludes that PCOS is a complex disorder caused by both genetic and environmental factors, affecting women's health in various ways, and requires personalized treatment.

research Evidence-Based Approach to Cutaneous Hyperandrogenism in Women

42 citations, July 2015 in “Journal of The American Academy of Dermatology”

The conclusion is that oral contraceptives and antiandrogens can treat hirsutism and acne in women with cutaneous hyperandrogenism, but more research is needed for effective treatments, especially for hair loss.

research An Updated Overview of Polycystic Ovary Syndrome

1 citations, June 2019 in “Innovare journal of medical sciences”

Polycystic Ovary Syndrome (PCOS) is a hormonal disorder in women that can cause infertility and other health issues, and it may be improved by treatments that increase insulin sensitivity.